{"id":60769,"date":"2024-02-28T07:07:38","date_gmt":"2024-02-28T07:07:38","guid":{"rendered":"https:\/\/medsname.com\/avonza\/"},"modified":"2026-05-08T09:18:45","modified_gmt":"2026-05-08T09:18:45","slug":"avonza","status":"publish","type":"product","link":"https:\/\/medsbase.com\/da\/avonza\/","title":{"rendered":"Avonza"},"content":{"rendered":"
\n

Hurtigt svar<\/h3>\n

Avonza<\/strong> er en specialist-superviseret antiretroviral terapi, der anvendes som del af en kombinationsbehandling mod HIV. L\u00e6s doserings-, bivirknings- og interaktionsafsnittene nedenfor f\u00f8r brug; ofte stillede sp\u00f8rgsm\u00e5l d\u00e6kkes i bunden.<\/p>\n<\/div>\n

\nHvad du f\u00e5r med MedsBase:<\/strong> WHO-GMP certificeret producent \u00b7 Diskret emballage \u00b7 Verdensomsp\u00e6ndende forsendelse \u00b7 1.400+ verificerede kundeanmeldelser<\/a>\n<\/div>\n

\ud83d\udce6 Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.<\/p>\n

Hvorfor bestille fra MedsBase<\/h3>\n

Vores generiske medicin kommer fra WHO-GMP certificerede producenter og sendes verdensomsp\u00e6ndende i diskret, neutral emballage \u2014 ingen medicinnavn p\u00e5 pakkens ydre. Kortbetalinger h\u00e5ndteres af en reguleret processor (kontoudtogsbeskrivelser inkluderer en reguleret betalingsprocessor \u2014 aldrig \u201cMedsBase\u201d eller medicinnavn). Crypto og SEPA bankoverf\u00f8rsel accepteres ogs\u00e5. Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy.<\/p>\n

Avonza<\/strong> is a fixed-dose combination antiretroviral tablet used for the treatment of HIV-1-infektion<\/strong>. Each tablet contains three active ingredients — Lamivudine 300mg<\/strong>, Tenofovir Disoproxil Fumarate 300mg<\/strong>, og Efavirenz 600mg<\/strong> — combined into a single daily pill. As a generic equivalent of Atripla<\/strong>, Avonza delivers the same triple-drug regimen at a fraction of the cost, making effective HIV treatment more accessible worldwide.<\/p>\n

When you buy Avonza online<\/strong> from MedsBase, you receive genuine, WHO-prequalified antiretroviral tablets manufactured under strict Good Manufacturing Practice (GMP) standards, shipped with discreet packaging and worldwide delivery. Browse our full range of HIV medications<\/a> for additional antiretroviral options.<\/p>\n

Avonza Product Overview<\/h2>\n

Avonza belongs to a class of medicines known as complete single-tablet regimens (STRs)<\/strong> for HIV-1. It combines two nucleoside reverse transcriptase inhibitors (NRTIs) with one non-nucleoside reverse transcriptase inhibitor (NNRTI), providing a complete antiretroviral therapy in one convenient tablet taken once daily.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Property<\/th>\nDetails<\/th>\n<\/tr>\n<\/thead>\n
Brand Name<\/td>\nAvonza<\/td>\n<\/tr>\n
Aktive ingredienser<\/td>\nLamivudine 300mg + Tenofovir Disoproxil Fumarate 300mg + Efavirenz 600mg<\/td>\n<\/tr>\n
L\u00e6gemiddelklasse<\/td>\nCombination antiretroviral (2 NRTIs + 1 NNRTI)<\/td>\n<\/tr>\n
Reference Brand<\/td>\nAtripla<\/td>\n<\/tr>\n
Form<\/td>\nFilm-coated oral tablet<\/td>\n<\/tr>\n
Dosering<\/td>\nOne tablet once daily<\/td>\n<\/tr>\n
Indikation<\/td>\nHIV-1 treatment in adults and adolescents ≥40kg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Avonza simplifies HIV-behandling<\/strong> by replacing what would otherwise be three separate medications into a single pill, improving adherence and reducing the complexity of daily antiretroviral therapy.<\/p>\n

How Avonza Works<\/h2>\n

Det Avonza tablet<\/strong> contains three antiretroviral agents that target HIV-1 at different stages of its replication cycle. By attacking the virus through multiple mechanisms simultaneously, Avonza suppresses viral load more effectively and reduces the risk of drug resistance.<\/p>\n

Lamivudine (300mg) — Nucleoside Reverse Transcriptase Inhibitor (NRTI)<\/h3>\n

Lamivudine (also known as 3TC) is a synthetic nucleoside analogue. Once inside an HIV-infected cell, it is phosphorylated to its active triphosphate form, which competes with the natural nucleoside deoxycytidine triphosphate. When incorporated into the growing viral DNA chain by reverse transcriptase<\/strong>, it causes chain termination<\/strong> — blocking further DNA synthesis and preventing the virus from replicating its genetic material.<\/p>\n

Tenofovir Disoproxil Fumarate (300mg) — Nucleotide Reverse Transcriptase Inhibitor (NtRTI)<\/h3>\n

Tenofovir is a nucleotide analogue that, like Lamivudine, inhibits HIV reverse transcriptase. However, because it is already a nucleotide (monophosphate), it requires one fewer phosphorylation step to become active. Tenofovir diphosphate competes with deoxyadenosine triphosphate and, when incorporated into viral DNA, causes obligate chain termination<\/strong>. Its distinct resistance profile complements Lamivudine, providing a robust NRTI backbone.<\/p>\n

Efavirenz (600mg) — Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)<\/h3>\n

Efavirenz works through a different mechanism from the two NRTIs. Rather than being incorporated into the DNA chain, it binds directly to HIV-1 reverse transcriptase<\/strong> at a site away from the active site (an allosteric site), causing a conformational change that disrupts the enzyme’s function. This non-competitive inhibition effectively shuts down viral DNA synthesis through an entirely separate pathway.<\/p>\n

Triple-Action Synergy<\/h3>\n

Together, these three components create a powerful barrier to HIV replication. The dual NRTI backbone (Lamivudine + Tenofovir) blocks reverse transcription through chain termination, while Efavirenz disables the same enzyme through allosteric inhibition. This multi-target approach<\/strong> is central to modern antiretroviral therapy — it suppresses the virus more completely and makes it significantly harder for HIV to develop resistance mutations against all three drugs simultaneously.<\/p>\n

\u2014 det forst\u00e6rker den normale fysiologiske respons snarere end at udl\u00f8se en kunstigt.<\/h2>\n

Avonza<\/strong> is indicated for the treatment of HIV-1-infektion<\/strong> as a complete regimen in the following patient populations:<\/p>\n

    \n
  • Voksne<\/strong> — treatment-naïve patients starting antiretroviral therapy for the first time, or patients switching from a stable regimen with undetectable viral load<\/li>\n
  • Adolescents weighing ≥40kg<\/strong> — who can swallow the tablet whole and require a complete single-tablet regimen<\/li>\n<\/ul>\n

    Important limitations:<\/strong><\/p>\n

      \n
    • Avonza is not indicated for pre-exposure prophylaxis (PrEP)<\/strong> — Efavirenz is not appropriate for HIV prevention in uninfected individuals<\/li>\n
    • Avonza is not effective against HIV-2<\/strong> — Efavirenz has no activity against HIV-2 reverse transcriptase<\/li>\n
    • Avonza should not be used as monotherapy<\/strong> or co-administered with other products containing the same active ingredients (e.g., separate Lamivudine, Tenofovir, or Efavirenz tablets)<\/li>\n<\/ul>\n

      Avonza Dosage<\/h2>\n

      The recommended dose of Avonza<\/strong> er one tablet taken once daily<\/strong>, on an empty stomach. Dosing at bedtime is strongly recommended to minimize central nervous system (CNS) side effects associated with Efavirenz, such as dizziness and vivid dreams.<\/p>\n

        \n
      • Tidspunkt:<\/strong> Take at bedtime, preferably 2–3 hours after the last meal<\/li>\n
      • Mad:<\/strong> Take on an empty stomach — taking with food (especially high-fat meals) increases Efavirenz absorption by up to 50%, which may worsen side effects<\/li>\n
      • Synk hel:<\/strong> Do not crush, break, or chew the tablet<\/li>\n
      • Konsistens:<\/strong> Take at the same time every day to maintain steady drug levels<\/li>\n
      • Glemt dosis:<\/strong> If you miss a dose, take it as soon as you remember unless it is almost time for the next dose — do not double up<\/li>\n<\/ul>\n

        No dose adjustment is needed for patients with mild renal impairment (creatinine clearance ≥50 mL\/min). Avonza should not be used<\/strong> in patients with moderate or severe renal impairment, as the Tenofovir component requires dose adjustment that cannot be achieved with a fixed-dose combination.<\/p>\n

        Benefits of a Single-Pill Regimen<\/h2>\n

        Taking a single tablet daily<\/strong> instead of multiple pills offers significant advantages for long-term HIV management:<\/p>\n

          \n
        • Improved adherence<\/strong> — simpler regimens lead to better medication-taking behaviour, which is critical for maintaining viral suppression<\/li>\n
        • Reduced pill burden<\/strong> — one tablet replaces three separate medications, reducing the daily reminder of living with HIV<\/li>\n
        • Lower risk of resistance<\/strong> — better adherence means fewer missed doses, which reduces the chance of the virus developing drug-resistant mutations<\/li>\n
        • Bekvemmelighed<\/strong> — easier to incorporate into a daily routine, especially for patients managing other health conditions<\/li>\n
        • Omkostningseffektiv<\/strong> — as a generic equivalent of Atripla, Avonza<\/strong> provides the same proven triple-drug combination at significantly lower cost<\/li>\n
        • Discreet<\/strong> — a single tablet is easier to store and take discreetly compared to multiple pill bottles<\/li>\n<\/ul>\n

          Avonza Side Effects<\/h2>\n

          Like all antiretroviral medications, Avonza<\/strong> can cause side effects. Most are mild to moderate and tend to improve within the first 2–4 weeks of treatment. The Efavirenz component is responsible for the majority of early side effects, particularly those affecting the central nervous system.<\/p>\n

          Almindelige bivirkninger<\/h3>\n\n\n\n\n\n\n\n\n\n
          Category<\/th>\nBivirkninger<\/th>\nHyppighed<\/th>\n<\/tr>\n<\/thead>\n
          Central Nervous System (Efavirenz)<\/td>\nDizziness, vivid or abnormal dreams, insomnia, impaired concentration, drowsiness<\/td>\nVery common (up to 50% in first weeks)<\/td>\n<\/tr>\n
          Gastrointestinal<\/td>\nNausea, diarrhoea, vomiting, abdominal pain<\/td>\nAlmindelige<\/td>\n<\/tr>\n
          Skin<\/td>\nRash (usually mild to moderate, resolves without stopping treatment)<\/td>\nAlmindelige<\/td>\n<\/tr>\n
          Metabolsk<\/td>\nElevated liver enzymes, elevated cholesterol and triglycerides<\/td>\nAlmindelige<\/td>\n<\/tr>\n
          General<\/td>\nTr\u00e6thed, hovedpine<\/td>\nAlmindelige<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

          CNS side effects from Efavirenz — particularly dizziness and vivid dreams — are very common during the first 1–2 weeks but typically resolve within 2–4 weeks<\/strong> of continued use. Taking the tablet at bedtime significantly reduces the impact of these effects on daily activities.<\/p>\n

          Alvorlige bivirkninger (sj\u00e6ldne)<\/h3>\n

          Seek immediate medical attention if you experience any of the following:<\/p>\n

            \n
          • Laktatacidose<\/strong> — symptoms include unusual muscle pain, difficulty breathing, stomach pain with nausea\/vomiting, cold or blue skin, and dizziness. This is a rare but potentially life-threatening complication of NRTIs (Lamivudine and Tenofovir).<\/li>\n
          • Hepatotoksicitet<\/strong> — severe liver damage presenting as jaundice (yellowing of skin or eyes), dark urine, pale stools, or persistent abdominal pain<\/li>\n
          • Hepatitis B flare<\/strong> — patients co-infected with Hepatitis B may experience severe acute exacerbations of hepatitis if Avonza is discontinued (see Warnings section below)<\/li>\n
          • Severe skin reactions<\/strong> — Stevens-Johnson syndrome (SJS) has been reported rarely with Efavirenz. Discontinue immediately if blistering or mucosal lesions develop.<\/li>\n
          • Psychiatric symptoms<\/strong> — severe depression, suicidal thoughts, or psychosis (uncommon but reported with Efavirenz)<\/li>\n
          • Nyresvigt<\/strong> — Tenofovir can affect kidney function, particularly proximal renal tubular function (Fanconi syndrome)<\/li>\n<\/ul>\n

            Important Warnings and Precautions<\/h2>\n

            Before starting Avonza HIV treatment<\/strong>, your healthcare provider should evaluate several important factors:<\/p>\n

              \n
            • Test for Hepatitis B before starting treatment<\/strong> — Lamivudine and Tenofovir are both active against Hepatitis B virus (HBV). If Avonza is stopped in a co-infected patient, the sudden removal of HBV suppression can trigger a severe hepatitis B flare<\/strong>. Monitor liver function closely for at least several months after discontinuation.<\/li>\n
            • Renal function monitoring<\/strong> — Tenofovir Disoproxil Fumarate can cause nephrotoxicity, including Fanconi syndrome and acute renal failure. Check serum creatinine and estimated creatinine clearance before starting therapy and at regular intervals during treatment. Avoid co-administration with other nephrotoxic agents.<\/li>\n
            • Bone density monitoring<\/strong> — Tenofovir has been associated with decreases in bone mineral density (BMD)<\/strong>. Consider monitoring in patients with a history of pathologic fracture or at risk for osteoporosis. Calcium and vitamin D supplementation may be beneficial.<\/li>\n
            • CNS effects<\/strong> — Efavirenz causes neuropsychiatric side effects in many patients. These usually resolve within 2–4 weeks<\/strong> but can persist in some individuals. Avoid driving or operating heavy machinery until you know how the medication affects you. Patients with a history of psychiatric disorders should be monitored closely.<\/li>\n
            • Graviditet<\/strong> — Efavirenz was previously associated with neural tube defects in animal studies. While more recent human data are reassuring, discuss the risks and benefits with your healthcare provider if you are pregnant or planning pregnancy.<\/li>\n
            • Immune reconstitution syndrome<\/strong> — when antiretroviral therapy is initiated, the recovering immune system may produce an inflammatory response to pre-existing infections (e.g., MAC, CMV, TB). This is not a reason to stop treatment.<\/li>\n<\/ul>\n

              L\u00e6gemiddelinteraktioner<\/h2>\n

              Efavirenz is a moderate inducer of CYP3A4<\/strong> and an inhibitor and inducer of CYP2B6<\/strong>, which means it can significantly alter the blood levels of many other medications. Lamivudine and Tenofovir have fewer drug interactions but should still be reviewed.<\/p>\n

              Contraindicated combinations (do NOT use with Avonza):<\/strong><\/p>\n